Names, dates, places, times, lies, legalized bribery, influence peddling, corrupt government agencies, bad drugs and bad people.
Now at Amazon:
Now at Amazon:
Introduction to: How Statin Drugs REALLY Lower Cholesterol:
While investigating statins, we were faced with big words like “3-Hydroxy-3-Methyl-Glutaryl Coenzyme-A reductase”, sometimes shortened to “HMG-CoA reductase” or better yet “reductase”. What to do?
To be understood, this report had to be simple.
Here is simple: we got shafted. The NIH and associated agencies blew over a half a billion dollars of our money. The FDA may as well have not existed. We have been lied to, stolen from and poisoned by the pharmaceutical industry.
No surprises here; business as usual.
Another part of biochemical language became apparent. Biochemistry is riddled with words and phrases like, “may, might, could, this might mean, putative (supposed), pleiotropic (many) and unknown mechanism”. The chemist might describe it something like this: “a proliferation of putative, pleiotropic inexactitudes”.
Is biochemistry an inexact science?
No. It is a science of proven results that are reproducible, consistent and understandable.
When it comes to approving drugs for profit it is easy to obscure proven results with caveats like “may or might or unknown mechanism”. After all, that is the language of biochemistry. When seeking FDA approval, those words become the lies of the pharmaceutical industry. Those words are honest words for unproven science; those are words that cannot be trusted when money is involved.
When it comes to drugs versus sound science, absolute science can be quickly obscured by the smoke screen of relative statistics.
Statistics don't lie, but liars use statistics.
Conflicts-of-interest become the enemy of a universally accepted proven scientific body of evidence. Absolute truths are buried by relative lies.
All of lipid theory “evidence” linking cholesterol to cardiovascular disease is based on relative statistics. True believers like Steinberg have agendas.
True believers are a dangerous lot. They fought on both sides in the crusades and presided over the Spanish Inquisition. They brought the Nazis to power in Germany and brought down the twin towers on 9/11.
Steinberg and his comrades are the true believers of this report. They skewed the statistics to save us from ourselves – even if it kills us. They are like the religious right that brought us prohibition, Al Capone, segregation and lynch mobs.
Scientists free of hidden agendas like Siperstein had proven statins were deadly long before a corrupted FDA approved them. Steinberg infected his colleagues and convinced the FDA that a deadly fungal toxin was good for all of us.
The drug companies that sell statins benefit from relative statistics used to obfuscate hard science. They dress it up with phrases like “evidence-based medicine”, “peer-reviewed report” and “double-blind study.” Dress up a pig, it is still a pig.
Misuse of statistics is a malignant cancer on medicine.
Two hundred million users at $2 per toxic dose and $400,000,000 per day yields enough gross resources to hire a whole army of ghostwriters to publish bogus claims and bury absolute science with relative statistics. This “malignancy” props up a $146,000,000,000 per year windfall to the drug industry—all built on lies.
This report tracks the liars and the lies about one of the statin drugs (lovastatin) from one of the drug companies (Merck). This is because lovastatin was the first of all the currently prescribed statins and Merck is responsible for its approval.
- Statin research was founded on scientific assumption and an agenda.
- Statins are dangerous drugs developed in error for profit.
- Scientific evidence had proven that statins were lethal years before lovastatin’s approval.
- Merck corrupted the science and the scientists.
- The approval process was so corrupted by Merck that lovastatin was bound to be approved.
- Merck lied.
- The FDA shirked its duty; neither safety nor efficacy was proven for statins.
- Statins are derived from fungal toxins that block cell growth and replication.
- Untold harm is being done to millions of human beings.
All of this is recorded in and gleaned from the public record.
In 1989, Thomas J. Moore wrote an investigative report called “The Cholesterol Myth”. He reviewed all the statistics published on three major NIH studies mounted with public funds (costing us over $500,000,000). He converted those relative statistics into their most understandable and absolute form. From his work, the following is clear:
- There is no credible proof that high blood cholesterol and cardiovascular disease (CVD) have a causal connection.
- Diet and exercise do not help.
- There is no good reason to prescribe statins to anyone.
If there was any justification for lowering cholesterol from NIH's $500,000,000 studies, and a safe way could be found, it should be administered to only one small group of men aged 28 to 45. The entire myth was built around that group.
Irrefutable, reproducible science proves statins are deadly and LDL cholesterol is vital for life. Universal biochemistry convention proves statins kill organs and organisms, one cell at a time.
This report expands on the following publicly recorded events:
- 1957: Japanese biochemist Akira Endo graduates from Tohoku University and joins Sankyo Pharmaceuticals in Tokyo. He receives a PhD in 1966 from Tohoku for his work at Sankyo.
- 1959: FDA approves MER/29 as the first cholesterol-lowering drug that blocked the mevalonate pathway and is an instant success.
- 1959-1961: Multiple reports are published hailing the benefits of MER/29 for lowering cholesterol.
- 1961: A MER/29 lab worker complains to her husband that lab animal data is falsified. Her husband, who car-pools with an FDA investigator, reports his wife's complaint. FDA performs an unannounced record search.
- 1962: MER/29 is removed from the market after FDA discovers the William S. Merrell Company had omitted preclinical findings of cataracts in rats and dogs, muscle wasting in monkeys and other falsified or unreported data.
- 1963: A federal grand jury indictment is issued against Merrell Co. and some of its employees. Scientists and executives plead “no contest”, which protects them against the grand jury findings in subsequent class-action civil suits. Multi-millions are awarded to the victims.
- 1960-1975: Drug companies enter the “mycotoxin gold rush” after a fungal toxin (aflatoxin) was found to cause cancer epidemics in grain-fed domestic trout and turkeys.
- 1970: Marvin Siperstein publishes his discovery that aflatoxin disrupts cholesterol synthesis in cells.
- 1971: Endo searches for cholesterol-lowering agents from fungal mycotoxins.
- 1976: Endo extracts citrinin, a disease-causing mycotoxin from Penicillium citrinum. He discovers that citrinin lowers blood cholesterol and publishes his report.
- 1976: Endo abandons his work with citrinin because it is too toxic. He extracts another mycotoxin from Penicillium citrinum called “ML-236B” which proves less toxic than citrinin and also lowers blood cholesterol. ML-236B becomes the first experimental statin.
- 1976: Endo contacts Dr. Goldstein at a Dallas-based Merck supported lab. Goldstein expresses interest in ML-236B.
- 1976: Merck contracts with Sankyo for the disclosure of information on ML-236B. Sankyo believes that both companies will jointly develop ML-236B.
- 1977: Endo, Brown and Goldstein publish a paper documenting how statins cause an increase in reductase. Statins are yet called “reductase inhibitors” instead of “reductase stimulators”.
- 1978: Merck develops their own statin. Sankyo cancels work with Merck. Endo leaves Sankyo.
- 1979: Endo patents another statin and sells it to Sankyo.
- 1979: Brown and Goldstein's mentor, Marvin Siperstein, co-authors a paper with astronaut Millie Hughes-Fulford. They explain how Endo's statin blocks DNA replication in cells and kills them.
- 1980: Brown and Goldstein co-author a paper explaining how statin-fed cells mutate and make more reductase or die.
- 1980: Sankyo cancels clinical trials on humans after half their lab dogs develop cancer.
- 1980: After receiving news of Sankyo’s decision to stop statin development, Merck calls Sankyo. Sankyo refuses to talk with Merck. Merck stops statin development.
- 1981: Brown and Goldstein report on cell mutations induced by statins.
- 1982: Under arrangements approved by the FDA, Merck makes lovastatin available to Grundy, Bilheimer and Brown at Dallas for FH patients who had failed known treatment modalities. An IND (Investigational New Drug) permit is granted for human experimentation in Dallas.
- 1984: Merck applies for an IND for lovastatin and a new drug application (NDA) is approved in nine months – one of the shortest approval times for the FDA since MER/29.
- 1985: The NIH launches the National Cholesterol Education Program (NCEP). Steinberg positions his colleague Grundy to chair the NCEP.
- 1985: Merck consultants Brown and Goldstein receive the Nobel Prize in Medicine for statin-related research. Their papers no longer report on statins’ deadly effects.
- 1987 (February 19): Brown and Steinberg represent Merck at the FDA advisory committee meeting on lovastatin. There is no disclosure on the increase in reductase and resultant cell injuries from mevalonate deprivation that are said, by Merck's MacDonald and Tobert, to be due to an unknown mechanism.
- 1987 (August): Lovastatin is FDA approved.
- 1987 (October): NCEP publishes cholesterol (statin) treatment guidelines in the American Heart Association’s (AHA’s) widely read “Circulation” magazine. The president of the AHA, Tony Gotto, is Merck’s consultant.
- 1990: The NIH convenes a panel to discuss the possibility that decreasing cholesterol levels might be intrinsically dangerous. The panel concludes that the evidence cannot be ruled out but dismisses it anyway.
- 2001: Bayer's “super-statin” Baycol is recalled after multiple deaths are attributed to the drug.
Greed smothers the conscience. Drug cartels, legal or illegal, pursue another agenda that rivals the evil of true believers. The vampire turns his hypnotic gaze on his victim: “You will live forever,” he whispers. He does not rightfully hiss, “You will sleep alone in a casket and never see the sun again.”
Today, statins remain the most insidiously dangerous and best-selling drug in the world.
In this book, “cardiovascular disease” is abbreviated as CVD. CVD includes coronary heart disease, atherosclerosis (hardening of the arteries), heart failure, high blood pressure and stroke.